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Abstract
Background: One hallmark of cancer cells is their ability to evade physiologic signals causing regulated cell death
(RCD). Correspondingly, TRAIL-based therapies to eliminate human cancer cells via enforced induction of apoptosis
have been established and represent a promising approach in anti-cancer research. However, due to frequently
appearing intrinsic or acquired resistances of tumor cells against apoptosis, TRAIL-based apoptotic strategies for the
treatment of cancer patients have shown limited efficacy. As a potential alternative, regulated necrosis (and necroptosis
triggered e.g. by TRAIL receptors 1/2) has recently gained considerable attention. Regulated necrosis represents a mode
of RCD molecularly distinct from apoptosis whose potential in anti-cancer therapy is almost uncharacterized. Since in
most cancer cells survival pathways counteract the effects of TRAIL-induced RCD, sensitizers such as cycloheximide
(CHX) are frequently added in cell culture to overcome this problem. Unfortunately, those sensitizers are cytotoxic and
therefore not suitable for the treatment of cancer patients. Here, we have alternatively employed homoharringtonine
(HHT), a plant alkaloid which was recently approved by the U. S. Food and Drug Administration to treat patients with
chronic myeloid lymphoma.
Results: We show that HHT is an efficient sensitizer for TRAIL-induced necroptosis in multiple human cancer cell lines.
In addition, HHT-enhanced TRAIL-mediated necroptosis occurs via the same signaling pathways (involving RIPK1/RIPK3/
MLKL) as CHX-enhanced necroptosis. Importantly, consecutive treatment schedules of necroptosis and apoptosis in
either combination revealed remarkable additive effects not reached by repetitive apoptotic treatments alone.
Conclusions: Taken together, our data demonstrate that HHT can replace harmful substances such as CHX to sensitize
human cancer cells to TRAIL-induced necroptosis. Thus, HHT represents a promising enhancer in TRAIL-based necroptotic
anti-cancer therapies also in patients.
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Background
Regulated cell death (RCD) is a critical element in the
manifestation of many human diseases, especially tumor
formation. Apoptosis is the best described form of RCD
and depends on the activation of caspases [1,2]. In con-
trast, necrosis has been classified for decades as a purely
accidental and uncontrolled type of cell death. Since the
discovery in 1988 that upon treatment with tumor ne-
crosis factor (TNF), cells showed either features of apop-
tosis or a necrotic balloon-like morphology without
nuclear disintegration, the concept that RCD can also
occur via regulated necrosis has been established by an
increasing number of studies ([3,4] reviewed in [5]). Also,
we and others have obtained evidence that regulated ne-
crosis may represent an alternative pathway for the
treatment of cancers that are resistant to apoptosis [6,7].
Because treatment with TNF is associated with strong
systemic toxic side effects, the cytokine TNF-related
apoptosis inducing ligand (TRAIL) has evolved as the
most promising alterative for cancer therapy (TRAIL in-
duces apoptosis in tumor cells while leaving non-
transformed cells mostly unaffected) [8-10]. Different
pre-clinical as well as phase I/II clinical studies demon-
strated no systemic toxicity of TRAIL to organs and
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tissues [11,12]. Unfortunately, many tumor cells are re-
sistant against TRAIL-induced apoptosis either intrinsic-
ally and/or via various anti-apoptotic signals from the
tumor microenvironment. The increased expression of
anti-apoptotic proteins such as Bcl-XL, cFLIP, or XIAP
and the reduced expression of pro-apoptotic molecules
such as caspases and Bid are just some examples of such
protective signals [13]. Since TRAIL-induced necroptosis
relies on completely distinct molecular pathways, it may
therefore represent an effective alternative method to se-
lectively eliminate these cancer cells [14-16].
Many recent studies have focused on boosting the effi-
ciency of TRAIL-induced apoptosis against tumor cells
by combined treatment with additional substances
[7,17-19] to overcome their resistances. For example,
CHX is widely used to sensitize tumor cells against
TNF/TRAIL-induced apoptosis, and we have previously
also used CHX to sensitize tumor cells against TRAIL-
induced necroptosis [7]. Unfortunately, in animal
models, CHX treatment causes severe side effects such
as liver damage [20]. Therefore, alternative non-toxic
sensitizing substances without such severe side effects
are needed for an effective TRAIL based therapy of
tumor patients.
In this study, we investigated the natural alkaloid HHT
(also known as omacetaxine mepesuccinate) as a poten-
tial non-toxic sensitizer for TRAIL-induced necroptosis.
In traditional Chinese medicine, HHT was obtained
from extracts from the bark of cephalotaxus species and
given to patients and the initial clinical study was re-
ported by the Cephalotaxus Research Coordinating
Group in 1976 [21]. HHT was used in the early 1980s
to directly treat chronic myeloid leukemia (CML) pa-
tients in China [22]. Since then, patients have been suc-
cessfully treated with HHT in multiple clinical studies
[23-26]. Finally, HHT was recently approved by the U. S.
Food and Drug Administration for treating patients with
chronic or accelerated phase chronic myeloid leukemia
with resistance and/or intolerance to two or more tyro-
sine kinase inhibitors [27,28]. Here, we show that HHT
represents an efficient sensitizer for TRAIL-induced
necroptosis in a panel of different tumor cell lines. These
findings implicate that HHT/TRAIL-induced necropto-
sis may also be successfully utilized in future therapy
regimens in cancer patients.
Results
HHT sensitizes human tumor cell lines to TRAIL-induced
necroptosis
We have previously demonstrated that the sensitivity of
tumor cells for TRAIL-induced necroptosis can be en-
hanced by the protein biosynthesis inhibitor CHX [7].
Moreover, we and others have found that treatment with
TRAIL normally activates caspase-dependent apoptosis.
Since this would interfere with the analysis of regulated
necrosis, caspases and apoptosis have to be actively
inhibited, e.g. by addition of the broad-spectrum caspase
inhibitor zVAD-fmk [7,14,29]. In a first set of experi-
ments, we tested whether treatment of cells with zVAD-
fmk in combination with TRAIL induced any cell death
and compared this to the induction of apoptosis by
treatment with TRAIL alone (Figure 1A). These experi-
ments clearly demonstrate that treatment with zVAD/
TRAIL is not sufficient to induce cell death in these hu-
man cancer cells and that sensitizers are indispensable.
In the next step we investigated the sensitizing effect of
increasing concentrations of HHT and CHX with or
without addition of TRAIL and in the presence of
zVAD-fmk (Figure 1B). The tumor cell lines tested in
these experiments were initially selected due to their dif-
ferential sensitivities to TRAIL-induced necroptosis they
had shown in a previous study, ranging from very sensi-
tive (Mz-ChA-1), well sensitive (HT-29), moderately sen-
sitive (A818-4) to being resistant (Pt45P1) [7]. In the
same study, the cell lines had also been verified for cell
surface expression of TRAIL receptors 1 and 2. Consist-
ent with this previous study, the four tumor cell lines
proved highly (Mz-ChA-1), moderately (HT-29, A818-4)
or not (Pt45P1) susceptible to TRAIL-induced necroptosis
when sensitized either with HHT or with CHX. From the
obtained data, we determined the optimal concentrations
of HHT and CHX which induced the highest rate of
TRAIL-mediated necroptosis while still being non-toxic in
the absence of TRAIL as follows: Mz-ChA-1: HHT-
0.1 μM, CHX-7.12 μM (corresponding to 2 μg/ml);
HT-29: HHT-1 μM, CHX-17.79 μM (5 μg/ml); A818-
4: HHT-0.1 μM, CHX-35.59 μM (10 μg/ml); Pt45P1:
HHT-0.01 μM, CHX-0.36 μM (0.1 μg/ml)). These op-
timal sensitizing concentrations were subsequently
used in the following experiments. To additionally
clarify whether HHT had any effect on membrane in-
tegrity by itself, we monitored cell death in HHT-only
treated cells over time (0, 2, 4, 6, 24 hours, using the
optimized concentrations determined above). As
shown in Figure 1C, HHT did not induce cell death
by itself, except for a minimal increase in A818-4 and
Pt45P1 cells at 24 h (the longest incubation time). Note-
worthy, HHT is able to sensitize cells for TRAIL-induced
necroptosis in the same manner as CHX, but in much
lower concentrations (Mz-ChA-1: 71-fold, i.e., 0.1 μM
HHT vs. 7.12 μM CHX, HT-29: 17-fold, i.e., 1 μM HHT
vs. 17.79 μM CHX, A818-4: 350-fold, i.e., 0.1 μM HHT vs.
35.59 μM CHX, Pt45P1: 36-fold, i.e., 0.01 μM HHT vs.
0.36 μM CHX).
We additionally validated these results in an independ-
ent experiment where we utilized the optimized concen-
trations of HHT and CHX to compare the sensitization
for TRAIL-induced necroptosis with the ability of HHT
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and CHX to sensitize for TRAIL-induced apoptosis
(Figure 2). As expected, all cell lines showed a compar-
able level of sensitization for necroptosis by the
optimized concentrations of HHT and CHX. This was
also observed for apoptosis (except for a slightly higher
sensitization by CHX in Pt45P1 cells), underscoring the
potential of HHT as a sensitizer also for apoptotic ther-
apy regimens and in agreement with a previous study
[30]. Notably, HHT and CHX were able to sensitize
Mz-ChA-1 and HT-29 cells for both necroptosis and
apoptosis, whereas A818-4 cells showed effective
sensitization only for necroptosis, and Pt45P1 cells for nei-
ther mode of RCD (Figure 2). Therefore, sensitization by
HHT or CHX for apoptosis does not automatically mean
sensitization for necroptosis and vice versa.
While performing the above experiments, the question
arose whether RCD induced by TRAIL/zVAD/HHT or
TRAIL/zVAD/CHX indeed occurred exclusively by
necroptosis or whether the presence of HHT or CHX
might still result in a (residual) apoptotic response, i.e.,
activation of caspases. We have previously demonstrated
in several studies and in multiple cell systems that no
features of apoptosis are detectable in the presence of 20
or 50 μM zVAD-fmk [4,14,31,32], but we nevertheless
decided to additionally clarify this issue in the very cell
lines utilized in this study. Poly(ADP-ribose) polymerase-1
(PARP-1) is a 116-kDa protein that is inactivated during
apoptosis by caspase-3-mediated cleavage to an 89-kDa
product [33]. Furthermore, the activation of caspase-8 as
an initiator caspase as well as of caspase-3 as an executor
caspase (i.e., cleavage from their precursors to the active
fragments) represent critical steps in apoptosis. Therefore,
the 89-kDa cleavage fragment of PARP-1 as well as
cleaved fragments of caspase-8 and caspase-3 represent
molecular markers for the occurrence of apoptosis. We in-
duced necroptosis in Mz-ChA-1, HT-29, A818-4 and
(See figure on previous page.)
Figure 1 HHT sensitizes cancer cells for TRAIL-induced necroptosis. (A) Cells were treated with TRAIL with or without pretreatment of 50 μM
zVAD-fmk to induce cell death in the absence of any additional sensitizers. (B) Cells were pretreated with 50 μM zVAD-fmk in combination with
0.01, 0.1, 1, and 10 μM of HHT or 0.36, 3.56, 7.12, 17.79 and 35.59 μM CHX (corresponding to 0.1, 1, 2, 5 and 10 μg/ml) for one hour before
100 ng/ml of TRAIL were added. (C) Cells were stimulated with optimized concentrations of HHT (red arrows in (B)) in a time course experiment
to monitor the cytotoxic effects of HHT alone. Loss of membrane integrity (after 24 h for panels A and B, as indicated for panel C) was measured
as a marker for cell death by flow cytometric detection of PI-positive cells. Each measurement represents the means of two independent experiments
with three parallel determinations each, error bars indicate the corresponding standard deviations (SDs). Red arrows indicate concentrations used for
further experiments.
Figure 2 Comparison of the sensitizing effect of HHT or CHX on TRAIL-induced necroptosis vs. apoptosis in tumor cells. Cells were pretreated
with 50 μM zVAD-fmk with or without HHT/CHX (Mz-ChA-1: HHT-0.1 μM, CHX-7.12 μM; HT-29: HHT-1 μM, CHX-17.79 μM; A818-4: HHT-0.1 μM,
CHX-35.59 μM; Pt45P1: HHT-0.01 μM, CHX-0.36 μM) and after one hour, 100 ng/ml of TRAIL were added. After 24 h, loss of membrane integrity
was measured as a marker for cell death by flow cytometric detection of PI-positive cells. Spontaneous cell death in untreated cells is shown for
comparison. Each bar represent the means of two independent experiments with three parallel determinations each, error bars indicate the
corresponding SDs. Asterisks indicate statistical significance (t-test; *, P < 0.05; **, P < 0.001; n.s., not significant). Co: Control, N: Necroptosis,
A: Apoptosis.
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Pt45P1 cells by treating them with TRAIL/zVAD/CHX or
TNF/zVAD/HHT. For control, we treated the cells with
zVAD/CHX or zVAD/HHT alone, induced apoptosis by
stimulation with TRAIL or with TRAIL/CHX, and add-
itionally tested cells treated with TRAIL/HHT in Western
blots for PARP-1 cleavage and for the presence of cleaved
fragments of caspase-8 and caspase-3 (Figure 3A-C). In all
cell lines, no increase in the levels of cleaved PARP-1
as well as cleaved caspase-8 and caspase-3 were de-
tectable during TRAIL/zVAD/CHX- or TRAIL/zVAD/
HHT-mediated RCD compared to the untreated and
zVAD/CHX or zVAD/HHT-controls. In contrast, after
induction of apoptosis by stimulation with TRAIL
alone or in combination with CHX, cleavage products
for PARP-1, caspase-8 and caspase-3 were clearly de-
tectable (Figure 3A-C). As an additional parameter,
we directly measured the activity of caspase-8 in Mz-
ChA-1 and HT-29 cells (Figure 3D). Compared to un-
treated cells, caspase-8 activity remained more or less
unchanged after stimulation with TRAIL/zVAD/HHT.
Figure 3 Treatment with TRAIL/zVAD/CHX or TRAIL/zVAD/HHT does not elicit apoptosis in tumor cells. (A-C) Cells were either left untreated or
pretreated with 50 μM zVAD-fmk with or without HHT/CHX (same concentrations as given in Figure 2). After one hour, 100 ng/ml of TRAIL were
added as indicated. After 24 h of stimulation, complete cell lysates were prepared. Identical amounts of protein (20 μg) were loaded on each lane
(from left to right: lane 1–3: negative controls, lane 4–5: necroptosis, lane 6–8: apoptosis as positive control) and PARP-1, cleaved caspase-8 and cleaved
caspase-3 were detected in Western blots. (A) The antibody against PARP-1 recognizes the 116-kDa full-length protein and the cleaved 89-kDa form
that is only visible in apoptotic lysates (TRAIL, TRAIL/CHX, TRAIL/HHT). (B) The antibody against caspase-8 recognizes the 18-kDa cleaved fragment that
is present only in apoptotic lysates (TRAIL, TRAIL/CHX, TRAIL/HHT). Asterisks: non-specific double band that does not match to the size of the 18-kDa
cleaved fragment of caspase-8. (C) The antibody against caspase-3 only recognizes the cleaved (active) form of caspase-3 that appears only in
apoptotic lysates (TRAIL, TRAIL/CHX, TRAIL/HHT). Detection of actin served as a loading control. (D) Caspase-8 activity was measured in Mz-ChA-1 and
HT-29 cells. Extracts were prepared from untreated (●) cells or from cells in which necroptosis (Δ) or apoptosis (□) had been induced as in (A-C), except
that pretreatment with zVAD-fmk was for 30 min and that stimulation time was 4 h. As a positive control (×), caspase activity in untreated extracts was
stimulated by the addition of dATP and cytochrome c; samples containing only buffer but no extracts served as negative control (○). Caspase-8 activity
was determined by measuring the cleavage of a fluorogenic peptide (zIETD-afc) in a time course over 75 minutes as described in Methods.
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In contrast, a clear increase in active caspase-8 was
detectable in apoptotic samples treated with TRAIL/
HHT. These results demonstrate that treatment with
TRAIL/zVAD/CHX or TRAIL/zVAD/HHT indeed
does not activate caspases in the tested cell lines. In
conclusion, RCD in response to TRAIL/zVAD/CHX
or TRAIL/zVAD/HHT occurs exclusively by necropto-
sis but not by apoptosis. As a further result of these
experiments, treatment with TRAIL/HHT lead to the
activation of caspase-8 and to a pronounced cleavage
of PARP-1, caspase-8 and caspase-3 in all cell lines
(Figure 3), demonstrating that HHT (like CHX) can
also act as an enhancer of apoptotic RCD.
HHT-enhanced TRAIL-induced necroptosis depends on
activation of RIP kinases
For the following experiments, we selected Mz-ChA-1
and HT-29 cells since these cells were most susceptible
to necroptosis (see Figure 1). Activation of receptor
interacting protein kinase 1 and 3 (RIPK1/RIPK3) is a
crucial step in the signaling pathways of necroptosis
[34]. We performed time kinetic experiments (0, 2, 4, 6
and 24 hours) to monitor whether the addition of HHT
caused alteration in these signaling pathways, e.g., whether
RIPK1 and RIPK3 activation did still occur as expected in
HHT-sensitized cells undergoing necroptosis (Figure 4A).
Within two hours after stimulation of Mz-ChA-1 or HT-
29 cells with TRAIL/zVAD/CHX (included for control) or
TRAIL/zVAD/HHT, higher molecular weight forms
(smear), in particular for RIPK3, were observed in Western
blots. As the most likely explanation, this increase in mo-
lecular weight is due to phosphorylation and activation of
these proteins when they trigger necroptosis. The intensity
of the detected RIPK1 and RIPK3 bands decreased after
24 hours of stimulation, indicating a termination of necrop-
totic signaling in the late to end stages of cellular disintegra-
tion (Figure 4A). Notably, inactivation of RIPK1 by cleavage
to a fragment of 42 kDa has been reported during apoptosis
[35]. Correspondingly, we observed a significant increase of
the 42-kDa RIPK1 cleavage fragment (which was present at
low levels already in untreated cells (Figure 4A, B)) when
we induced apoptosis with TRAIL in Mz-ChA-1 and HT-
29 cells. In contrast, no inactivation of RIPK1 by cleavage
was detectable when necroptosis was triggered by TRAIL/
zVAD/CHX or TRAIL/zVAD/HHT (Figure 4A, B), consist-
ent with the importance of functional RIPK1 in necroptosis.
To validate whether activation of RIP kinases is indeed es-
sential also for progression of HHT-enhanced necroptosis,
cells were treated with necrostatin-1s (Nec-1s) which is an
efficient inhibitor of RIPK1 [36,37]. In our experiments,
Nec-1s was able to completely block TRAIL-induced
necroptosis (but had no effect on apoptosis; P for Mz-ChA-
1 cells was 0.045 and thus only marginally below the signifi-
cance threshold of 0.05) either sensitized by HHT or CHX
(Figure 4C), clearly confirming the relevance of RIPK1 in
HHT- or CHX-enhanced TRAIL-induced necroptosis.
HHT-enhanced TRAIL-induced necroptosis occurs via
phosphorylation and activation of MLKL
In the next step we checked whether crucial compo-
nents of necroptotic signaling downstream of RIPK1 and
RIPK3 are modulated in HHT-enhanced necroptosis and
compared this to CHX-enhanced necroptosis in Mz-
ChA-1 and HT-29 cells. For this purpose, we investi-
gated mixed lineage kinase domain-like protein (MLKL)
which is a critical downstream target of RIPK3 [38,39].
Because it is well established that MLKL is phosphory-
lated during necroptosis leading to its activation, we
used an antibody that exclusively recognizes the phos-
phorylated form of MLKL (pMLKL) and compared that
to signals from an MLKL antibody that recognizes the
unphosphorylated form of the protein [39,40]. In un-
stimulated lysates and lysates from cells two hours after
stimulation either with TRAIL/zVAD/CHX (included for
control) or TRAIL/zVAD/HHT, we were not able to de-
tect pMLKL (Figure 5A). In contrast, after four hours of
stimulation, pMLKL was detectable and the signal sig-
nificantly increased over time, which clearly shows that
MLKL gets activated by phosphorylation in HHT (as
well as CHX)-enhanced TRAIL-induced necroptosis.
Conversely, we were not able to detect any pMLKL in
TRAIL-induced apoptotic samples (Figure 5B). We then
used necrosulfonamide (NSA) that covalently binds to
MLKL in human cells to block execution of regulated
necrosis [39]. The data obtained in this experiment
clearly showed that in both cell lines, NSA was able to
completely block TRAIL-induced necroptosis sensitized
with HHT or CHX (Figure 5C). Interestingly, NSA sen-
sitized the cells for apoptosis in the control as well as
when HHT or CHX were present. This may point to fur-
ther yet unknown targets of NSA and/or to an additional
undiscovered role of MLKL in the suppression of apop-
tosis. Taken together, we show that HHT-enhanced
TRAIL-induced necroptosis leads to phosphorylation of
MLKL as a known critical component of the necroptotic
signaling pathway, comparable to CHX-enhanced TRAIL-
induced necroptosis.
Downregulation of RIPK3 and MLKL protects from TRAIL/
zVAD/HHT-mediated necroptosis.
To additionally validate the above experiments with in-
hibitors of RIPK1 and MLKL, and to also include func-
tional targeting of RIPK3, we performed siRNA studies
to specifically downregulate RIPK1, RIPK3 and MLKL
(Figure 6). Furthermore, we employed two additional in-
dependent methods to detect cell death in our samples
(measurement of ATP levels (Figure. 6A) and the release
of lactate dehydrogenase (LDH) (Figure 6B)). Compared
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to the negative control (non-target siRNA), downregula-
tion of RIPK1 did not change the levels of cell death sig-
nificantly after TRAIL/zVAD/HHT stimulation. This is
in contrast to the above results using Nec-1s, but might
be due to remaining amounts of RIPK1 after downregu-
lation that are still sufficient to promote RIPK1-RIPK3
complex formation and subsequently recruitment of
MLKL by RIPK3 to execute necroptosis [41]. In contrast,
downregulation of RIPK3 and MLKL resulted in a statis-
tically significant protection of the cells after stimulation
with TRAIL/zVAD/HHT, confirming their role in HHT-
enhanced TRAIL-induced necroptosis.
Cells undergoing HHT-enhanced TRAIL-induced necroptosis
show typical necrotic morphologies
In addition to the fundamental differences at the
molecular level, apoptosis and necroptosis can be distin-
guished macroscopically. While in apoptosis the forma-
tion of apoptotic vesicles (blebbing) is a characteristic
feature, in necroptosis the cells form a balloon-like
morphology without nuclear disintegration [42]. In order
to clarify whether the addition of HHT caused any atyp-
ical alterations of necroptosis that were detectable at the
level of cellular morphology, we compared HHT- and
CHX-sensitized Mz-ChA-1 and HT-29 cells after induc-
tion of necroptosis and apoptosis with TRAIL (Figure 7).
In this experiment, we included A818-4 and Pt45P1 cells
to clarify if these moderately or not necroptosis-
susceptible cell lines would show any morphologic
changes upon stimulation or not. In all cases where we
induced apoptosis (TRAIL, TRAIL/HHT and TRAIL/
CHX treatment), the formation of apoptotic vesicles
could be observed (black arrows). These vesicles were
not detectable when we induced necroptosis (TRAIL/
zVAD/HHT and TRAIL/zVAD/CHX treatment). In these
samples, the typical swelling of cells undergoing necrop-
totic cell death was visible (white arrows). Overall, cells
treated with HHT showed no differences in cell morph-
ology compared to cells treated with CHX or without
sensitizer. These results implicate that the addition of
HHT sensitizes cells for necroptosis (or apoptosis) with-
out altering the morphology or the intracellular signaling
pathways of the cell.
Consecutive induction of necroptosis and apoptosis
eliminates cancer cells with higher efficiency
Finally, we investigated whether a consecutive induction
of apoptosis and necroptosis gives advantages for the
elimination of cancer cells (i.e., treatment of cells to in-
duce necroptosis or apoptosis and successive treatment
of the surviving cells to induce either apoptosis and
necroptosis a second time or alternatively to kill
remaining apoptosis-resistant cells by necroptosis and
vice versa; Figure 8). In these experiments we could
show that after induction of apoptosis (Mz-ChA-1: 40%
cell death, HT-29: 31% cell death), a second treatment of
the surviving cells with TRAIL to again induce apoptosis
resulted in levels of cell death that were comparable to
those observed after the initial treatment. In contrast to
that, necroptosis as a second stimulus showed signifi-
cantly higher levels of cell death in the cells that had
survived apoptosis (Mz-ChA-1: 78% with HHT and 82%
with CHX; HT-29: 77% with HHT and 63% with CHX).
This clearly demonstrated that cells surviving apoptosis
could be efficiently eliminated via necroptosis, and also
confirmed the efficiency of necroptotic cell death.
Nevertheless, the induction of necroptosis as a second
treatment did not cause higher levels of cell death than
in experiments where necroptosis was induced as a first
treatment (right panels), indicating that an induction of
apoptosis does not further increase the sensitivity of cells
for necroptosis. In the reverse approach, cells that sur-
vived an initial induction of necroptosis however showed
a higher sensitivity towards a consecutive induction of
apoptosis (Mz-ChA-1: 70% cell death after HHT and
60% cell death after CHX, HT-29: 75% cell death after
HHT and 47% cell death after CHX) compared to a con-
secutive treatment of solely apoptosis in both treatments
(Mz-ChA-1: 40%, HT-29: 31%). In case of a second, con-
secutive induction of necroptosis in cells that had sur-
vived a first induction of necroptosis, we similarly
observed high levels of cell death (Mz-ChA-1: 86.5% cell
death after HHT and 84.5% cell death after CHX, HT-
29: 72% cell death after HHT and 65% cell death after
CHX), indicating that the surviving cells had not devel-
oped resistance against necroptosis, and possibly point-
ing to a generally decreased likeliness of cancer cells to
(See figure on previous page.)
Figure 4 HHT-enhanced TRAIL-induced necroptosis depends on activation of RIPK1/RIPK3 and can be blocked by necrostatin-1s (Nec-1s).
(A, B) Cells were pretreated with 50 μM zVAD-fmk with HHT (Mz-ChA-1: 0.1 μM; HT-29: 1 μM) or CHX (Mz-ChA-1: 7.12 μM; HT-29: 17.79 μM) or
left untreated, and after one hour, 100 ng/ml of TRAIL were added. Cell lysates were prepared at the indicated time points after stimulation
and RIPK1 (including its 42-kDa cleavage fragments) and RIPK3 were detected by Western blot. Detection of actin served as a loading control.
(C) Cells were preincubated with 50 μM Nec-1s for one hour and stimulated as indicated in (A). After 24 h, loss of membrane integrity was
measured as a marker for cell death by flow cytometric detection of PI-positive cells. Cell death in the corresponding controls is shown for
comparison (white bars). Each bar represents the means of two independent experiments with three parallel determinations each, error bars indicate
the corresponding SDs. The addition of Nec-1s significantly reduced the level of necroptosis compared to cells not treated with Nec-1s, regardless of
the presence of HHT or CHX. Asterisks indicate statistical significance (t-test; *, P < 0.05; **, P < 0.001; n.s., not significant). Co: Control, N: Necroptosis,
A: Apoptosis.
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become necroptosis-resistant. Especially for Mz-ChA-1
cells, less than 40,000 surviving cells (marked with #)
were detectable in flow cytometry after the second treat-
ment. Taken together, these data suggest that a consecu-
tive induction of necroptosis and apoptosis represents a
more efficient strategy for the elimination of cancer cells
than a single induction of either mode of RCD.
Discussion
Many tumors are resistant to TRAIL-induced apoptosis
and even combinations of TRAIL with sensitizing agents
were only partially effective in a number of clinical trials
(reviewed in [43]). Thus, alternative ways to kill those re-
sistant cancer cells have to be investigated. The caspase-
independent mode of RCD mediated by death receptors
termed as necroptosis turned out as a feasible way to elim-
inate cancer cells in a previous study [7]. However, in most
cancer cells, survival pathways counteract the effects of
TRAIL-induced RCD, which makes sensitizers such as
CHX indispensible to overcome this problem. Unfortu-
nately, those sensitizers are cytotoxic by themselves and
cannot be used in treatment of cancer patients.
Here we show that HHT, an U. S. Food and Drug
Administration-approved anti-leukemia drug, efficiently
sensitizes for TRAIL-induced necroptosis in similar way
as known for CHX. We selected cell lines that were
highly, moderately, or not susceptible to TRAIL-induced
necroptosis when sensitized with CHX and compared
this to HHT sensitization. We found that the tested
cells reacted with comparable levels of cell death. In
agreement with previous data we could show that HHT
is also able to sensitize for TRAIL-induced apoptosis
[30]. This resulted in higher levels of PARP-1 as well as
caspase-3 cleavage, whereas no such cleavage products
were detectable in necroptosis. In addition, no cleavage
or increased activity of caspase-8 was observed in
necroptotic samples compared to untreated cells,
whereas cleavage and activation was clearly detectable
in apoptotic samples. Taken together, these data clearly
confirm that necroptosis and not apoptosis was in-
duced by treatment with TRAIL/zVAD/HHT.
In necroptosis triggered by death receptors, activation
of RIPK1 and RIPK3 to form the necrosome is a critical
event [44]. Recently, MLKL has also been identified as
an additional component that interacts with RIPK3. For
TNF-induced necroptosis, MLKL with mutated phos-
phorylation sites prevented the activation of the necro-
some [39,45]. Our Western blot data and the outcome
of experiments with the inhibitors Nec-1s and NSA
clearly show that HHT-sensitized necroptosis depends
on this RIPK1/RIPK3/MLKL signaling that forms the
necrosome, in the same manner as CHX-sensitized
necroptosis. In addition, our morphological studies show
that HHT does not alter the cell morphology within the
effective doses for sensitization. This underlines our
findings that HHT can substitute CHX to sensitize can-
cer cells to necroptosis. Importantly, we show that a
stepwise treatment with different combinations of
necroptosis and apoptosis can result in better elimin-
ation of cancer cells. For example, Mz-ChA-1 cells that
were more resistant to apoptosis after the first round of
treatment could be eliminated via induction of necropto-
sis in the second round of treatment. Interestingly, these
cells could also be sensitized for apoptosis after a first
treatment via necroptosis. In addition, we show that cells
that survived an initial induction of necroptosis could be
further efficiently killed by a second induction of
necroptosis. These findings imply a possible application
of HHT as a sensitizer in the elimination of cancer cells
that are apoptosis resistant and, because HHT is an
already U. S. Food and Drug Administration-approved
anti-leukemia drug, it may be used in different combina-
tions in patients with apoptosis resistant tumors in fu-
ture experiments. However, as the next step, HHT-based
treatments (consecutive and/or in combination) have to
be investigated in mouse xenotransplantation models for
their efficiency to kill apoptosis-resistant cancer cells by
necroptosis.
(See figure on previous page.)
Figure 5 HHT-enhanced TRAIL-induced necroptosis occurs via activation of the downstream signaling component MLKL. (A) Activation of MLKL
was checked by Western blot of its unphosphorylated and phosphorylated forms during a time course of 24 h. Cells were prestimulated with
50 μM zVAD-fmk with HHT (Mz-ChA-1: 0.1 μM; HT-29: 1 μM) or CHX (Mz-ChA-1: 7.12 μM; HT-29: 17.79 μM), followed by addition of 100 ng/ml of
TRAIL after one hour. Cell lysates were prepared at the indicated time points after stimulation and loaded on a SDS gel (20 μg per lane). The
unphosphorylated and phosphorylated forms of MLKL were detected by Western blot and detection of actin served as loading control.
(B) Phosphorylation of MLKL was not detected in Mz-ChA-1 and HT-29 cells after induction of apoptosis with 100 ng/ml TRAIL for the
indicated time points. 20 μg of protein was analyzed per lane, actin served as loading control and necroptotic samples were loaded for
control. (C) Cells were preincubated with necrosulfonamide (NSA, specific inhibitor of MLKL) for one hour and afterwards stimulated as
indicated in (A). After 24 h, loss of membrane integrity was measured as a marker for cell death by flow cytometric detection of
PI-positive cells. Cell death in the corresponding controls is shown for comparison (white bars). Each bar represents the means of two
independent experiments with three parallel determinations each, error bars indicate the corresponding SDs. The addition of NSA significantly reduced
the level of necroptosis compared to cells not treated with NSA, regardless of the presence of HHT or CHX. Asterisks indicate statistical significance
(t-test; **, P < 0.001). As part of the same experiment shown in Figure 4C, the same negative control values were used. For clarity of presentation, the
data of Nec-1s- (Figure 4C) and NSA-stimulated cells are shown in two separate figures. Co: Control, N: Necroptosis, A: Apoptosis.
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As a potent inhibitor of translation, HHT combined
with TRAIL may negatively affect healthy cells, as for ex-
ample reported for the anti-cancer proteasome inhibitor
bortezomib [46]. It has been shown that induction of
apoptosis by HHT in combination with TRAIL reduced
the growth of tumor xenotransplants (HT-29) in immu-
nodeficient mice within the therapeutic window [30].
Recent studies clearly demonstrate the anti-cancer ef-
fects of HHT also in patients with acute promyelocytic
leukemia (APL). Patients with HHT treatment showed
an improved 5-year overall survival rate of 92.6 ± 0.6%
(versus 89.9 ± 0.5%; P > 0.05) and a 5-year disease free
survival rate of 100% (versus 86.8 ± 0.6%; P > 0.05) [47].
This and other studies demonstrate that HHT can be
safely used in patients, and also suggests that HHT-
sensitized necroptosis may likewise safely be employed
in future therapy regimens in cancer patients.
As an important point to consider for future therapies,
the authors of a recent study [48] raise the intriguing
concept that within a tumor, yet unidentified mecha-
nisms of regulated necrosis cause the death of tumor
cells within the central core, and in consequence pro-
voke neovascularization, which in turn promotes growth
of the residual tumor. In that sense, a tumor would
Figure 6 Downregulation of RIPK3 and MLKL protects from TRAIL/zVAD/HHT-mediated necroptosis. Mz-ChA-1 and HT-29 cells were transfected
using siPORT™ Amine with siRNAs specific for human RIPK1, RIPK3, or MLKL, or – as a negative control – with a non-target siRNA (NT) that does
not elicit an RNAi response. 72 h after transfection, cells were treated with 50 μM zVAD in combination with 0.1 μM HHT (Mz-ChA-1) or 1 μM
HHT (HT-29) for one hour before 100 ng/ml TRAIL were added. After 24 h, the decrease of intracellular ATP levels (A) and release of LDH (B) was
determined as a marker for cell viability or cytotoxicity, respectively. ATP and LDH levels are shown relative to controls that were not treated with
TRAIL/zVAD/HHT. ATP measurements are shown as means of five independent experiments with five parallel determinations each. In each LDH
measurement, one out of two representative experiments with five parallel determinations each is shown. Error bars indicate the corresponding
SDs. Asterisks indicate statistical significance (t-test; *, P < 0.05; **, P < 0.001). Control Western blots of untreated transfected cells were performed
to verify the downregulation of endogenous human RIPK1, RIPK3 and MLKL. Detection of actin served as loading control.
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benefit from driving itself into necroptosis rather than
being eliminated. However, in this model, only the
central core of a tumor is “sacrificed” to necroptosis
to promote the accelerated growth of the remaining,
neovascularized peripheral part of the tumor. In a fu-
ture treatment of patients however, necroptosis would
be induced in a way to target and eliminate all cells
of a tumor within a short timeframe, a) probably
leaving not enough time to allow for neovasculariza-
tion, and b) hopefully not allowing peripheral tumor
cells around the central core to survive and benefit
from the central cells dying from necroptosis. With
regard to the question whether necroptosis is benefi-
cial or detrimental for tumor growth, Colbert and co-
workers have recently demonstrated that in pancreatic
ductal adenocarcinoma, patients with low tumoral
MLKL expression have a poor prognosis [49], indicat-
ing that high levels of MLKL expression (and thus
susceptibility to necroptosis) are beneficial for pa-
tients and detrimental for tumors. Nevertheless, a
final resolution of this question will have to await fur-
ther studies, such as the analysis of orthotopic xeno-
transplantation models in mice and finally, studies in
patients.
Figure 7 Characteristic morphological features of HHT-enhanced TRAIL-induced necroptosis and apoptosis in tumor cells. Cells were stimulated
as indicated in the legend to Figure 2. Micrographs are showing the morphology of cells after 24 h of treatment (to have a direct comparison to
the other performed experiments) as indicated on the left. In each micrograph, two typical morphologies of TRAIL-induced necroptosis (white
arrows) and apoptosis (black arrows) are indicated. In Pt45P1 cells, no necroptosis was visible as these cells are resistant to this type of cell death.
These cells were used as an additional control to monitor if HHT/CHX treatment results in morphological changes of the cells not related to cell
death. Scale bar: 100 μm.
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Figure 8 (See legend on next page.)
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Methods
Cell lines and culture conditions
The gallbladder adenocarcinoma cell line Mz-ChA-1
and the pancreatic adenocarcinoma cell lines A818-4
and Pt45P1 have been described [50-52]. The colorectal
adenocarcinoma cell line HT-29 cells was originally ob-
tained from the American Type Culture Collection. Mz-
ChA-1, A818-4 and Pt45P1 cells were cultured in RPMI
1640 (Life Technologies, Darmstadt, Germany) sup-
plemented with 10% v/v FCS, 10 mM glutamine and
1 mM sodium pyruvate. HT-29 cells were cultured in
McCoy’s supplemented with 10% v/v FCS, 10 mM
glutamine. All cells were kept in a humidified incu-
bator containing 5% w/v CO2. Necroptosis was in-
duced by addition of human recombinant TRAIL
(SuperKillerTRAIL™, Enzo, Lausen, Germany) in com-
bination with benzyloxycarbonyl-Val-Ala-Asp(OMe)-
fluoromethylketone (zVAD-fmk; Bachem, Heidelberg,
Germany) and CHX (Sigma-Aldrich, Deisenhofen,
Germany) or HHT (Santa Cruz Biotechnology, Heidelberg,
Germany). Nec-1s and NSA were purchased from Merck
Millipore, Darmstadt, Germany.
Cytotoxicity assays
Cell death was measured by propidium iodide uptake
after loss of membrane integrity. For flow cytometric
analysis, cells were seeded onto 12-well plates at 70%
confluence. 24 hours after treatment, cells were detached
by accutase (Life Technologies), collected and washed
once in PBS/5 mM EDTA. Pelleted cells were resus-
pended in PBS/5 mM EDTA containing 2 μg/ml propi-
dium iodide (PI), and subsequently analyzed in a
FACSCalibur flow cytometer (BD Biosciences, San
Diego, CA, USA) at red fluorescence.
Western blot
Whole cell lysates were prepared with TNE lysis buffer
(50 mM Tris pH 8.0, 150 mM NaCl, 1% v/v NP-40,
3 mM EDTA, Complete protease inhibitor mixture
(Roche, Mannheim, Germany)) on ice. Proteins (20 μg
per lane) were separated by SDS-PAGE, transferred onto
nitrocellulose membranes and reactive proteins were
detected with antibodies against RIPK1 (610459, BD
Biosciences), RIPK3 (PAB0287, Abnova, Heidelberg,
Germany), MLKL (2103620, Sigma-Aldrich), pMLKL
(phospho S358, ab187091, Abcam, Cambridge, UK),
PARP-1 (9542, Cell Signaling, Danvers, USA), caspase-8
(1C12, 9746, Cell Signaling), cleaved caspase-3 (9661,
Cell Signaling) or actin (A1978, Sigma-Aldrich) by
chemiluminescence (LumiGLO, Cell Signaling).
RNA interference
The siRNAs specific for human RIPK1 (D-004445-03),
RIPK3 (D-003534-01) as well as the negative control
siRNA (#1, D-001206-13) were obtained from Thermo
Scientific (Schwerte, Germany). The siRNA specific for
human MLKL (S47087) was purchased from Life Tech-
nologies. Mz-ChA-1 and HT-29 cells were transfected
with siPORT™ Amine agent (AM4502, Life Technolo-
gies). For each transfection (96-well-based assay for ATP
and LDH measurements), 0.6 μl of siPORT Amine
agent was mixed with 9.4 μl of Opti-MEM® medium
(11058021, Life Technologies) and incubated at room
temperature for 10 min. Afterwards, 2 pmol/μl of siRNA
were added, incubated for additional 10 min at room
temperature before 80 μl of cell suspension at a density of 6
× 103 cells was added. Cells were incubated for additional
72 h at 37°C before ATP and LDH measurements were per-
formed. For Western blot analysis, the same procedure was
performed in 12-well plates using 10 times the volume of
each reagent.
ATP and LDH measurements
Measurement of intracellular ATP was performed with
the CellTiterGlow® luminescent cell viability assay
(G7570, Promega, Mannheim, Germany) and lumines-
cence intensity was measured on white 96 well flat bot-
tom plates with an Infinite M200 microplate reader
(Tecan, Crailsheim, Germany). The release of LDH was
detected directly in cell culture by the cytotoxicity detec-
tion KitPlus (04744934001, Roche) according to the
manufacturer’s protocol and measured with an Infinite
M200 microplate reader (absorbance at 450 nm, back-
ground absorbance at the reference wavelength of
(See figure on previous page.)
Figure 8 Consecutive induction of necroptosis and apoptosis eliminates cancer cells with higher efficiency. Cells were stimulated as indicated
with 50 μM zVAD-fmk or not and with HHT (Mz-ChA-1: 0.1 μM; HT-29: 1 μM) or CHX (Mz-ChA-1: 7.12 μM; HT-29: 17.79 μM). After one hour,
100 ng/ml of TRAIL were added or not as indicated. After 24 h, loss of membrane integrity was measured as a marker for cell death by flow
cytometric detection of PI-positive cells (1st treatment). In a parallel experiment, after 24 h of treatment, the supernatant was discarded and
adherent, viable cells (green columns) were washed with medium. After 24 h of reconstitution in medium, cells were treated again as indicated.
After another 24 h, cells were measured as before via PI-staining (2nd treatment). Each bar represents the means of two independent experiments
with three parallel determinations each, error bars indicate the corresponding SDs. In the 1st treatment, both HHT and CHX treatments were
performed as part of the same experiment using the same controls. Therefore, the same control values are shown in the two respective panels.
The same applies to the 2nd treatment. Asterisks indicate statistical significance (t-test; *, P < 0.05; **, P < 0.001; n.s., not significant). Due to the high
levels of cell death of Mz-ChA-1 cells after the first induction of necroptosis, less than 40,000 cells could be measured after the second induction (#). Co:
Control, N: Necroptosis, A: Apoptosis.
Philipp et al. Cell Communication and Signaling  (2015) 13:25 Page 14 of 16
600 nm). The average absorbance values of the samples
and controls, each in 5 repeats, were calculated by sub-
traction of the background absorbance from the mea-
sured absorbance. As controls, the spontaneous LDH
activity in cell culture medium (low control, Lc) and the
maximum releasable LDH activity after cell lysis (high
control, Hc) were determined. The cytotoxicity (% of
LDH release) was calculated as: [(treated mean – Lc
mean)/(Hc mean – Lc mean)] × 100.
Analysis of caspase-8 activity
Activity of caspase-8 was measured as described previ-
ously [4]. Mz-ChA-1 and HT-29 cells were collected and
lysed in a buffer containing 10 mM Hepes pH 7.4,
142 mM KCl, 5 mM MgCl2, 1 mM EGTA, 0.2% v/v
NP40, 1 mM DTT and 2 mM Pefabloc (Roche). Positive
controls were produced out of 20 μg of cell lysate, that
was equilibrated for 1 h at 30°C after the addition of
1 mM dATP and 10 μM cytochrome c to permit activa-
tion of caspases. Subsequently, 100 μl of caspase buffer
(20 mM Pipes, 100 mM NaCl, 10 mM DTT, 1 mM
EDTA, 0.1% w/v CHAPS, 10% w/v sucrose, pH 7.2)
containing 100 μM zIETD-afc (benzyloxycarbonyl-Ile-
Glu(OMe)-Thr-DL-Asp(OMe)-7-aminotrifluoromethylcou-
marin, Merck Millipore) were added to 10 μl of cytosolic
extract (0.5 μg protein) and incubated at 37°C. The release
of afc was then measured as emission at 505 nm upon exci-
tation at 405 nm using an Infinite M200 fluorimeter
equipped with a thermostated plate reader.
Microscopy
For documentation of cell morphology, images from
unfixed cells were obtained using an Axiovert 10 micro-
scope (Zeiss, Oberkochen, Germany) and a DS-5 M-L1
digital sight camera system (Nikon, Düsseldorf, Germany).
Statistical analysis
P values were calculated using Student’s t-test. Statistical
significance is denoted by *P < 0.05 and **P < 0.001.
Abbreviations
CHX: Cycloheximide; HHT: Homoharringtonine; LDH: Lactate dehydrogenase;
PI: Propidium iodide; RCD: Regulated cell death; SD: Standard deviation;
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